Mortimer C H, Besser G M, McNeilly A S, Marshall J C, Harsoulis P, Tunbridge W M, Gomez-Pan A, Hall R
Br Med J. 1973 Oct 13;4(5884):73-7. doi: 10.1136/bmj.4.5884.73.
A standard intravenous 100 mug luteinizing hormone/follicle stimulating hormone-releasing hormone (LH/FSH-RH) test was used to assess the pituitary gonadotrophin responses in 155 patients with a variety of diseases of the hypothalamic-pituitary-gonadal axis. In all but nine patients there was an increase in circulating levels of either LH or FSH in response to the releasing hormone though 137 (88%) were clinically hypogonadal. It was not possible with this test to distinguish between hypothalamic and pituitary causes of hypogonadotrophic hypogonadism, since a variety of LH and FSH responses emerged within the disease groups. However, primary gonadal failure characteristically resulted in exaggerated gonadotrophin response. The potential therapeutic use of the gonadotrophin releasing decapeptide is suggested in certain patients with hypogonadotrophic hypogonadism.
采用标准静脉注射100微克促黄体生成素/促卵泡激素释放激素(LH/FSH-RH)试验,评估了155例患有下丘脑-垂体-性腺轴各种疾病患者的垂体促性腺激素反应。除9例患者外,其他所有患者对释放激素的反应均表现为LH或FSH循环水平升高,尽管其中137例(88%)临床性腺功能减退。由于疾病组内出现了多种LH和FSH反应,因此该试验无法区分性腺功能减退性性腺功能减退的下丘脑和垂体病因。然而,原发性性腺功能衰竭的特征是促性腺激素反应过度。对于某些性腺功能减退性性腺功能减退患者,提示了促性腺激素释放十肽的潜在治疗用途。